Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

• Citi’s 2024 Global Healthcare Conference – Miami, FLBo Cumbo, President and CEO, will participate in a panel discussion titled “Neuromuscular Disorders” on Wednesday, December 4, 2024, at 1:00 p.m. ET.

• Piper Sandler 36th Annual Healthcare Conference – New York, NYMr. Cumbo and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat on Thursday, December 5, 2024, at 9:30 a.m. ET.

Live webcasts of the Citi panel discussion and Piper Sandler fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management during the conference may reach out to their Citi or Piper Sandler representatives.

About Solid BiosciencesSolid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:Nicole AndersonDirector, Investor Relations and Corporate CommunicationsSolid Biosciences [e-mail]

Media Contact:Glenn SilverFINN [e-mail]